14.50

0.48% 0.008

Enanta Pharmaceuticals Inc (ENTA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$14.51

Aprire:

$14.66

Volume 24 ore:

21,062

Relative Volume:

0.11

Capitalizzazione di mercato:

$423.67M

Reddito:

$69.21M

Utile/perdita netta:

$-61.98M

Rapporto P/E:

-5.5891

EPS:

-2.5947

Flusso di cassa netto:

$-9.61M

1 W Prestazione:

+0.00%

1M Prestazione:

+29.26%

6M Prestazione:

+4.97%

1 anno Prestazione:

+90.59%

Intervallo 1D:

$14.38

$14.86

Intervallo di 1 settimana:

$14.38

$15.51

Portata 52W:

$6.435

$17.15

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Nome

Enanta Pharmaceuticals Inc

Settore

Healthcare (1100)

Industria

Biotechnology (615)

Telefono

617 607 0800

Indirizzo

4 KINGSBURY AVENUE, WATERTOWN, MA

Dipendente

120

Cinguettio

@EnantaPharma

Prossima data di guadagno

2026-08-10

Ultimi documenti SEC

ENTA's Discussions on Twitter

Compare ENTA vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ENTA Enanta Pharmaceuticals Inc	14.57	423.96M	69.21M	-61.98M	-9.61M	-2.5947
VRTX Vertex Pharmaceuticals Inc	518.01	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	662.52	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	927.05	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	317.43	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	187.49	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-26	Iniziato	Rodman & Renshaw	Buy
2025-11-14	Iniziato	JP Morgan	Overweight
2025-10-01	Aggiornamento	Jefferies	Hold → Buy
2025-07-28	Ripresa	H.C. Wainwright	Buy
2023-08-09	Downgrade	JP Morgan	Neutral → Underweight
2023-08-08	Downgrade	Jefferies	Buy → Hold
2022-12-09	Iniziato	H.C. Wainwright	Buy
2022-07-06	Aggiornamento	Evercore ISI	In-line → Outperform
2022-06-01	Aggiornamento	Evercore ISI	Underperform → In-line
2021-10-07	Iniziato	Jefferies	Buy
2021-09-09	Iniziato	SVB Leerink	Mkt Perform
2021-01-29	Aggiornamento	JP Morgan	Underweight → Neutral
2020-11-24	Iniziato	Evercore ISI	Underperform
2020-08-28	Ripresa	ROTH Capital	Buy
2020-08-26	Iniziato	Piper Sandler	Overweight
2020-07-27	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2020-03-17	Aggiornamento	Robert W. Baird	Neutral → Outperform
2019-11-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2019-09-26	Downgrade	JP Morgan	Neutral → Underweight
2019-05-24	Iniziato	Wolfe Research	Outperform
2019-04-23	Aggiornamento	Berenberg	Hold → Buy
2018-12-13	Iniziato	Berenberg	Hold
2018-06-06	Iniziato	ROTH Capital	Buy
2018-02-08	Downgrade	JP Morgan	Overweight → Neutral
2018-01-02	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2017-11-21	Reiterato	RBC Capital Mkts	Outperform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2017-07-11	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2016-04-28	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Reiterato	Barclays	Underweight
2015-10-23	Downgrade	Barclays	Equal Weight → Underweight
2015-10-23	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform

Mostra tutto

Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie

Jul 02, 2026

Federal Circuit Rules Written Description Standard Governs Patent Priority In Enanta Pharmaceuticals v. Pfizer (PFE) - londoninsider.co.uk

Jul 02, 2026

Jul 01, 2026

Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView

Jul 01, 2026

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry - Moomoo

Jun 28, 2026

Enanta Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo

Jun 28, 2026

Jun 27, 2026

AbbVie, Enanta announce EU label expansion for hepatitis C therapy, Maviret - MSN

Jun 27, 2026

Enanta Pharmaceuticals (ENTA) moves 5.2% higher: Will this strength last? - MSN

Jun 27, 2026

Jun 26, 2026

Enanta Pharmaceuticals sets out pipeline catalysts, shares watched by biotech investors - AD HOC NEWS

Jun 26, 2026

Enanta Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ENTA) - TradingView

Jun 26, 2026

Jun 25, 2026

Pfizer patent win against Enanta over COVID pill upheld by appeals court - MSN

Jun 25, 2026

Price to book forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView

Jun 25, 2026

Price to earnings forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView

Jun 25, 2026

Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView

Jun 25, 2026

Price to book forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView

Jun 25, 2026

ENTA Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

PATENT—Fed. Cir.: Pfizer Inc. prevails in coronavirus-treatment patent dispute with biotechnology company - VitalLaw.com

Jun 24, 2026

Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance

Jun 24, 2026

EC approves label expansion for Enanta’s Maviret in acute HCV infection - The Pharma Letter

Jun 24, 2026

Form 8K Enanta Pharmaceuticals Inc For: 23 June - Investing.com UK

Jun 24, 2026

Jun 23, 2026

Federal appeals court upholds invalidity of Enanta patent in Pfizer case By Investing.com - Investing.com South Africa

Jun 23, 2026

Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com South Africa

Jun 23, 2026

Federal appeals court upholds invalidity of Enanta patent in Pfizer case - Investing.com UK

Jun 23, 2026

H.C. Wainwright reiterates Enanta stock rating on FDA alignment - Investing.com UK

Jun 23, 2026

Enanta Faces Patent Setback in Paxlovid Litigation - TipRanks

Jun 23, 2026

H.C. Wainwright reiterates Enanta stock rating on FDA alignment By Investing.com - Investing.com South Africa

Jun 23, 2026

[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event - Stock Titan

Jun 23, 2026

CAFC Affirms Enanta Coronavirus Patent Invalid for Lack of Written Description Support in Provisional Application - IPWatchdog.com

Jun 23, 2026

Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral - Bloomberg Law News

Jun 23, 2026

Enanta (ENTA) Secures EU Approval for Maviret Treatment - GuruFocus

Jun 23, 2026

ENTA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus

Jun 23, 2026

Enanta Pharmaceuticals? Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - marketscreener.com

Jun 23, 2026

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - BioSpace

Jun 23, 2026

H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Jun 23, 2026

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET - Business Wire

Jun 23, 2026

Jun 22, 2026